Corona Remedies IPO Date, Review, Price and Key Information

Corona Remedies Limited IPO is fully book build issue and total IPO size is ₹1600 crores. The offering includes a fresh issue worth ₹800 crores and an offer for sale of ₹800 crores.

The dates for the Corona Remedies Limited IPO have not been announced yet. The allotment process is expected to be finalized by [.].

The Corona Remedies Limited IPO is scheduled to list on BSE, NSE, with a listing date of [.]. The price band for the Corona Remedies Limited IPO has not been announced yet.

Registrar for this IPO is Bigshare Services Private Limited and lead managers for Corona Remedies Limited IPO are Jm Financial Limited, Iifl Capital Services Limited, Kotak Mahindra Capital Company Limited.

IPO Schedule

IPO Open Date	-
IPO Close Date	-
IPO Allotment Date	-
Refund Initiation	-
Share credit in Demat	-
Listing Date	-

Key Details

Price Band	TBA
Lot Size	TBA
Face Value	₹10 Per Equity Share
Total Issue Size	₹1,600.00 Crores
Fresh Issue	₹800.00 Crores
OFS Issue	₹800.00 Crores
Issue Type	Fresh issue and Offer for Sale
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	75%
Retail	10%
NII/HNI	15%

About Corona Remedies Limited Company

J.B. Chemicals & Pharmaceuticals Limited (Consolidated): For the nine months ended December 31, 2024, the company reported revenue from operations of INR 2,968.51 crore, reflecting a growth of 13.20% compared to the same period last year. Domestic revenue contributed 59% of the total, while international revenue accounted for 41%. Gross profit stood at INR 1,974 crore, with a gross profit margin of 66.50%. EBITDA reached INR 805 crore, resulting in an EBITDA margin of 27.10%. Profit after tax was INR 513.89 crore, with a PAT margin of 17.00%.

Corona Remedies Limited Financial Details

Period Ended	31 Dec 2024	31 Dec 2023	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	8702.06	8138.74	8305.76	5950.24	5113.63
Revenue	902.73	748.63	1014.47	884.05	617.33
Profit After Tax	117.88	67.74	90.50	84.93	-0.40
Net Worth	5750.51	4579.34	4804.07	4085.20	3209.06
Reserves and Surplus	513.89	396.77	419.25	347.36	269.86
Total Borrowing	61.00	155.89	134.14	2.33	33.74

₹ In Crore

Key Performance Indicator

Basic EPS (in ₹)	Return on Net Worth (RoNW)	Net Asset Value (NAV)	Debt-Equity Ratio	Return on Equity (ROE)	Return on Capital Employed (ROCE)
14.80	18.84%	78.55

Offer Objectives

The Offer comprises an Offer for Sale (OFS) of equity shares with a face value of ₹10 each, aggregating up to ₹800 crore. The primary objective is to achieve the benefits of listing on the stock exchanges, enhancing visibility, brand recognition, and providing liquidity to existing shareholders.

The selling shareholders and their respective maximum amounts are as follows:

Dr. Kirtikumar Laxmidas Mehta: Up to ₹160 crore
Minaxi Kirtikumar Mehta: Up to ₹94.4 crore
Dipabahen Niravkumar Mehta: Up to ₹12.8 crore
Brinda Ankur Mehta: Up to ₹12.8 crore
Sepia Investments Limited: Up to ₹491.4 crore
Anchor Partners: Up to ₹18.37 crore
Sage Investment Trust: Up to ₹10.23 crore

The company will not receive any proceeds from the Offer, which will be distributed to the selling shareholders proportionally, after deducting offer-related expenses and taxes. The estimated total expenses for the Offer are approximately ₹[●] million, covering listing fees, commissions, legal counsel fees, registrar fees, and marketing expenses. These expenses will be borne pro rata by the selling shareholders based on the number of equity shares sold by each of them.